explore -WSS

explore

author：fashion 2025-09-28 02:33:06 - browse：6183

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.

AstraZeneca will pay $2 billion in cash upfront for Fusion, a price that at $21 a share is nearly double Fusion’s closing share price on Monday. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Fusion specializes in developing radiopharmaceuticals, also known as radioconjugates or radioligands, which deliver radiation directly to tumors, guided by particular markers on cancer cells. The aim is not only to minimize the risk of damaging surrounding, healthy tissue, but also to reach tumors that traditional radiation can’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Listen: Racing for gene therapy & a pioneering approval

entertainment

WSS

Gut bacteria may contribute to kidney autoimmunity, study finds

Evacuations in place as 3 wildfires burn in eastern Washington state

Gut bacteria may contribute to kidney autoimmunity, study finds

Congress must give Medicare recipients genetic counseling access

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Eye stem cell transplant could help restore vision in injured people

hotspot

explore

explore

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

Activists slam private health insurers over coverage restrictions

Medicare Advantage 2025 payments will dip, Biden administration says

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Dobbs anniversary: the lost opportunity of abortion as health care

Baltimore teen accused of firing into crowd during block party mass shooting

BioMarin wins approval for gene therapy to treat hemophilia A

Scientists uncover potential path to treating deadly childhood tumor

focus

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

Cancer drug shortages' outsize impact on ovarian cancer patients

ActiGraph execs on goal of drug approvals with digital endpoints

Clinical trials must include more disabled people

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

leisure time

entertainment

hotspot

hotspot